Upregulation of CLS-1 and tafazzin-1 and downregulation of ALCAT-1 by elamipretide favor improvement in cardiolipin synthesis and remodeling that can potentially elicit beneficial effects in cardiomyopathic hearts associated with Barth syndrome. The gene discussed is LCLAT1; the disease is Barth syndrome.